<code id='15F5D0DAD8'></code><style id='15F5D0DAD8'></style>
    • <acronym id='15F5D0DAD8'></acronym>
      <center id='15F5D0DAD8'><center id='15F5D0DAD8'><tfoot id='15F5D0DAD8'></tfoot></center><abbr id='15F5D0DAD8'><dir id='15F5D0DAD8'><tfoot id='15F5D0DAD8'></tfoot><noframes id='15F5D0DAD8'>

    • <optgroup id='15F5D0DAD8'><strike id='15F5D0DAD8'><sup id='15F5D0DAD8'></sup></strike><code id='15F5D0DAD8'></code></optgroup>
        1. <b id='15F5D0DAD8'><label id='15F5D0DAD8'><select id='15F5D0DAD8'><dt id='15F5D0DAD8'><span id='15F5D0DAD8'></span></dt></select></label></b><u id='15F5D0DAD8'></u>
          <i id='15F5D0DAD8'><strike id='15F5D0DAD8'><tt id='15F5D0DAD8'><pre id='15F5D0DAD8'></pre></tt></strike></i>

          Home / hotspot / knowledge

          knowledge


          knowledge

          author:entertainment    Page View:349
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In